To study the effect of type 2 diabetes (T2D) on vascular wall inflammation and hematopoietic stem cell composition in vivo, and whether these changes can be reversed with glucagon like peptide 1 receptor (GLP1R)-agonism.
We will use 68Ga-Dotatate PET/CT scans, bone marrow aspirations and peripheral blood analyses to determine the effect of type 2 diabetes on vascular wall inflammation, and hematopoietic stem cell composition, and whether these changes can be reversed using high dose semaglutide treatment, up to 2.0mg subcutaneously per week, for a period of six months.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
22
Semaglutide 2.0 mg/mL, administered subcutaneously once per week for a period of 6 months.
AMC
Amsterdam, North Holland, Netherlands
RECRUITINGDifference in coronary 68Ga-Dotatate uptake after treatment.
The within subject comparison of 68Ga-Dotatate uptake in the coronary arteries before and after semaglutide treatment, expressed as a difference in TBRmax.
Time frame: 6 months
Difference in bone marrow aspirates after treatment.
The within subject comparison of bone marrow aspirates before and after semaglutide treatment, expressed as a difference in stem cell count.
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.